Stifel reiterated a Buy rating and an $85.00 price target on Cooper Companies (NASDAQ:COO) stock after the company's Q2 fiscal 2026 earnings call. This decision follows Cooper Companies actively pursuing the sale of CooperSurgical and settling a fertility-related case, which analysts believe clears the path for a pure-play CooperVision (contact lens) business. Stifel's analysis suggests an 18% upside from current levels, despite the company lowering its full-year revenue guidance and other firms adjusting price targets due to the planned divestiture.

UniFirst Corporation shareholders have approved the company's acquisition by Cintas Corporation. The deal, valued at $155 in cash and 0.7720 shares of Cintas stock per UniFirst share, garnered approval from over 99% of votes cast. The transaction is anticipated to close in the second half of 2026, subject to customary closing conditions and regulatory approvals.

Baidu's Apollo Go, in partnership with Swiss Post's PostBus, has received a Level 4 driverless operating permit from Switzerland’s Federal Roads Office. This approval allows for hands-free, open-road pilot trials in Eastern Switzerland, with regular fully driverless public transport operations projected to begin by early 2027. This marks Apollo Go's significant expansion into Europe following its substantial growth in autonomous rides globally.

ArrowMark Financial (NASDAQ:BANX) has declared a monthly cash distribution of $0.15 per share for June 2026, maintaining its established payout rate. This decision follows strong first-quarter 2026 earnings, where net investment income of $0.52 per share (or $0.46 per share based on absolute outstanding shares) exceeded the $0.45 quarterly target distribution requirement. The distribution is payable on June 30, 2026, to shareholders of record as of June 23, 2026.

KLA Corporation's stock surged 12% ahead of its 10-for-1 split due to analyst upgrades and strong guidance from CFO Bren Higgins. Higgins highlighted increased visibility into the 2027 wafer fabrication equipment market and significant growth in KLA's advanced packaging process control revenue, projected to reach $1 billion in 2026. The company continues to widen its market share in process control, with aggressive targets for future gains, although potential downside risks include China policy escalation.

Morgan Stanley analysts suggest the Federal Reserve's policy focus is shifting towards "firmer inflation" rather than concerns about "weaker hiring." This change is influenced by recent inflation data, persistent energy price spikes due to the U.S.-Israeli assault on Iran, and a robust labor market. The analysts outline scenarios where inflation could run higher, leading the Fed to maintain or even hike rates.

Maamoun Rajeh has been appointed to lead Arch Capital Group Ltd.'s Insurance, Reinsurance, and Mortgage segments, taking on expanded responsibilities as the company transitions to a single president model. Rajeh, who joined Arch in 2001 and previously built Arch Re into a leading global provider, will now also oversee the Insurance segment. This move follows the departure of David Gansberg, with CEO Nicolas Papadopoulo expressing confidence in Rajeh's deep understanding of the Property and Casualty business.

Gilead Sciences is donating over 2,000 vials of its antiviral therapy, remdesivir, to Uganda to aid in its Ebola Bundibugyo virus disease (BVD) outbreak response. This effort continues Gilead's long-standing commitment to addressing emerging infectious diseases and supporting global health emergencies. The company is also preparing to provide remdesivir and obeldesivir to other regional partners and support clinical trials for Ebola BVD.

Ademi LLP is investigating AvalonBay (NYSE: AVB) for potential breaches of fiduciary duty related to its recently announced transaction with NextEra Energy. The investigation focuses on whether AvalonBay shareholders are receiving a fair price, as they will own only approximately 51.2% of the combined company, and also examines potential restrictions on competing transactions and benefits for AvalonBay insiders. Shareholders are encouraged to contact Ademi LLP for more information.

BioCryst Pharmaceuticals presented new clinical trial data and real-world evidence for its hereditary angioedema (HAE) portfolio at the EAACI 2026 Annual Meeting. The data showed sustained efficacy for its commercial drug Orladeyo in pediatric patients and positive subgroup analysis for its investigational antibody, navenibart, reinforcing their potential for reducing HAE attack rates. These results strengthen the commercial positioning of Orladeyo and validate navenibart's potential for flexible dosing in the rare disease market.